Institutional Support Propels MRK to Outperform Dji in 2024
In 2024, as $DJIA(.DJI)$ crept upward, the global pharmaceutical giant $Merck(MRK)$ has shone brightly, with its stock price soaring 16.8% year-to-date, comfortably outpacing the index.
This surge is fueled primarily by institutional support, evidenced by billionaire Kenneth Griffin's Citadel Advisors snapping up 1.25 million shares of Merck in Q2 2024.
Keytruda: The Growth Catalyst
At the heart of its recent success lies Keytruda, a blockbuster cancer immunotherapy drug. Keytruda maintains its first-mover advantage in treating first-line non-small cell lung cancer, solidifying its position as the best-in-class therapy in immuno-oncology.
Analysts forecast a robust revenue growth of 14.7% for Merck in 2024 and 2025, impressive for a seasoned blue-chip firm. This growth, coupled with the high margins of cancer drugs, is poised to significantly boost the company's overall operating profitability.
However, investors should keep an eye on the looming expiry of Keytruda's US patent in 2028, which could pose a significant threat to Merck's long-term revenue streams.
Attractive Valuation and Dividend Yield
Currently trading at a dynamic P/E ratio of 14.5, Merck's stock is significantly below the industry average of 17, suggesting it may be undervalued compared to its peers. Plus, its juicy dividend yield of 2.45% is backed by a diversified portfolio that ensures stability and safety of payouts.
Yet, Merck's heavy reliance on Keytruda is a double-edged sword. While the drug has fueled impressive financial performance over the years, it also poses a potential risk. With rapid advancements in oncology research, any erosion of Keytruda's market position could significantly impact Merck's earnings.
Billionaire and Institutional Backing
With institutional ownership hovering around 78%, Merck enjoys strong confidence from professional investors. Kenneth Griffin's Citadel Advisors' purchase of 1.25 million shares in Q2 2024 underscores top investors' bullish stance.
Known for his shrewd investment strategies, Griffin's bet signals his conviction that Merck will continue to outperform. However, retail investors should proceed with caution when following so-called "smart money."
Remembering, institutional investors may buy a stock for reasons beyond its upside potential. For instance, Merck could be part of Citadel's broader hedging strategy. Therefore, don't blindly jump in just because billionaires are loading up.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
